Health News Releases

  • Today September 27
September 30, 2022 09:10
Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany
Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany. The new facil
Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
September 29, 2022 13:43
Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
Johnson & Johnson (the “Company”) (NYSE: JNJ) today took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New
September 28, 2022 17:10
Biocytogen to Present at BioJapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduc
THUNDERBEAT Open Fine Jaw Type X surgical energy device.
September 28, 2022 16:34
Olympus Launches THUNDERBEAT Energy Device for Open Surgery
Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer, and more fulfilling, today announced the release of the THUNDERBEAT(TM) Open Fine Jaw Type
September 27, 2022 17:40
New Survey from Philip Morris International Reveals Strong Societal Support for Disruptive Innovations to Drive Public Health Progress
A new international survey released today by Philip Morris International Inc. (PMI) (NYSE: PM) reveals that despite broad public support for disruptive innovation to address global challenges, issues
Michelle Bonfilio
September 27, 2022 17:15
Covetrus Names Michelle Bonfilio as Chief People Officer
Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and
September 23, 2022 13:30
Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660,
September 22, 2022 15:00
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
Merck, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective an
September 22, 2022 14:35
Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck
Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing
September 20, 2022 17:20
Galderma Debuts The Sensitive Skincare Faculty, a Global Expert Group to Improve Understanding and Management of Sensitive Skin
Reinforcing its commitment to advancing dermatology for every skin story, Galderma announced today the formation of a global Sensitive Skincare Faculty, which will focus its efforts on helping people
September 20, 2022 10:30
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
Takeda (TSE:4502/NYSE:TAK) and Enel North America today announced the signing of a long-term virtual power purchase agreement (VPPA) for the electricity delivered to the power grid from a 79 megawatt
September 19, 2022 14:10
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis
LEO Pharma A/S, a global leader in medical dermatology, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opi
September 19, 2022 10:30
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of maribavir for the treatment of cy
September 19, 2022 09:40
Olympus Launches VISERA ELITE III Surgical Visualization Platform
Olympus Corporation (“Olympus” - Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced the launch of VISERA ELITE III, its newest surgical visualization platfo
September 16, 2022 15:40
Hyperice Brings the Heat With Introduction of All-New Venom Go and Venom 2
Hyperice, a global high-performance wellness brand, today announced two new products within their heat therapy category, Venom Go and Venom 2, alongside HyperHeat™ technology for the fastest, most con
September 16, 2022 11:55
DentalMonitoring Launches DM Insights
DM Insights joins the DM Intelligent Platform, DentalMonitoring’s full suite of solutions designed to improve the quality of care and the patient experience while growing practices at the same time. M
September 16, 2022 11:20
UAE’s Burjeel Medical City Successfully Carries Out Its First Kidney Transplant
Providing an option for local and international patients to undergo kidney transplantation in private hospitals in the UAE’s Abu Dhabi, Burjeel Medical City (BMC) has started performing kidney transpl
September 15, 2022 15:30
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based
September 15, 2022 14:00
Prolific Machines Raises $42M From Top Planetary Health Investors to Build the Assembly Line for Biology
Prolific Machines, a next generation biotechnology company, is emerging from stealth today by announcing their massively oversubscribed Seed and Series A financings, led by the best VCs in the space.
September 14, 2022 17:30
Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
Takeda (TSE:4502/NYSE:TAK) today announced four new partnerships to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare for people in d
September 14, 2022 16:00
VeriSilicon Announces the One-Stop VeriHealth Chip Design Platform for Smart Healthcare Applications
VeriSilicon (688521.SH), a leading Silicon Platform as a Service (SiPaaS®) company, today announced the launch of its customizable one-stop health chip design platform-VeriHealth™. Based on VeriSilico
September 14, 2022 13:55
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints
September 13, 2022 16:40
Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors
Rhizen Pharmaceuticals AG (Rhizen), a Swiss based privately held, clinical-stage biopharmaceutical company announced today that it is presenting data from an ongoing Phase 2 trial of Tenalisib in loca
September 13, 2022 11:15
PDC*line Pharma Presents First Clinical Results From Phase I/II trial With PDC*lung01 at ESMO 2022
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the first results of PDC-LUNG-101 phase I/II clinica
September 08, 2022 16:50
Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care
Merck, a leading science and technology company, today announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly
September 08, 2022 16:50
Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
Merck, a leading science and technology company, today announced the latest research from the Company’s oncology portfolio and pipeline to be presented at this year’s European Society of Medical Oncol
September 07, 2022 14:30
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Públi
September 07, 2022 10:50
Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG
Lysando AG - market leader in the field of antimicrobial proteins - is pleased to announce that Fabian Geldmacher, M.D., has joined the team as Director Strategy & Business Development in June. Dr. Ge
September 06, 2022 16:00
GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress
Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022. These include on-
September 06, 2022 10:30
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Today, Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents between 6 and 17
Discovery process of high-grade serous ovarian cancer (HGSOC) biomarker candidates
September 06, 2022 10:21
Research Results of New Biomarker for Ovarian Cancer Diagnosis through Bertis’ Platform Published in Journal of Proteome Research
Bertis, a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced that the research results of their search for protein biomarkers for early
September 05, 2022 16:45
CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 20
September 02, 2022 16:55
U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults
The U.S. Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psoriasis (GPP) flares in adults, Boehringer Ingelheim anno
September 02, 2022 15:30
Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, sh
September 01, 2022 17:10
Aster Guardians Global Nursing Award 2023 Worth US $250,000 is Now Open for Nominations from Nurses Worldwide
In its continued efforts to recognize the contribution of nurses to mankind and to the healthcare community, Aster DM Healthcare has announced the next edition of the Aster Guardians Global Nursing Aw
HK inno.N CI
September 01, 2022 14:19
GICELL to Collaborate with HK inno.N on Research and Development for next-generation CAR-NK Therapy
GICELL announced research and development collaboration for allogeneic CAR-NK candidates with HK inno.N on August 29th, 2022. The companies plan to advance the development of numerous CAR-NK therap
August 31, 2022 09:00
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the
August 30, 2022 18:00
Aleph Farms Joins AIM for Climate as Newest Innovation Sprint Partner to Advance Cellular Agriculture
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that it has been officially recognized by the Agriculture Innovatio
August 29, 2022 14:45
Covetrus Names Margie B. Pritchard General Counsel
Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben
August 29, 2022 13:30
The Polypill Reduces Cardiovascular Mortality by 33% in Patients Treated After Myocardial Infarction
The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardio
August 26, 2022 14:00
PCI Pharma Services Opens New England Center of Excellence to Bring Global Clinical Supply Capabilities to New England
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the opening of its Clinical Services Center of Excellence in Bridgewater, MA, th
August 25, 2022 15:40
Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio
Galderma: Continued strong commercial and financial performance in a resilient market · Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year o
August 25, 2022 13:30
Biocytogen Expands Partnership with Merck
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice™ platform. Under the terms of the agreement, Merc
August 25, 2022 10:30
AdvanCell Closes A$18M Series B Funding Led by Morningside
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Serie
August 24, 2022 16:20
Morinaga Milk Obtains FDA GRAS Notification for its Probiotic
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium longum subsp. infantis M-63 has received FDA GRAS (Ge
August 24, 2022 14:40
Frazier Life Sciences Adds Senior R&D Leader to Team
Frazier Life Sciences announced the addition of Annette Doherty, Ph.D., OBE, FRSC as a Senior Advisor. She has 35 years of international experience as a chemist and leader of pharmaceutical research a
Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
August 23, 2022 17:00
Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled
August 23, 2022 16:50
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment
August 23, 2022 16:20
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
Takeda (TSE:4502/NYSE:TAK) today announced the company’s dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and F
August 23, 2022 14:00
Medisca Unveils New Brand Identity and Corporate Positioning as Partners in Wellness
After three successful decades of redefining, shaping, and informing the pharmaceutical compounding industry standard, Medisca is proud to unveil a new global brand identity and corporate positioning
25 per page50 per page75 per page100 per page